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ABSTRACT 
Purpose: A retrospective study was conducted to calculate biological objective functions 
[Tumor control probability (TCP) for the prostate and normal tissue complication probability 
(NTCP), in particular for the rectum] for patients treated at Johannesburg hospital during the 
years 2002 – 2003 for prostate cancer and to correlate these values with observed clinical 
outcome. Ultimately these results were used to evaluate the effects of dose escalation on 
tumor control and rectal complications following radiotherapy using conformal external beam 
radiotherapy.  
 
Methods and materials: To calculate the TCP and the NTCP use was made of BIOPLAN, a 
PC-based software. This software allows the user to evaluate a treatment plan from the point 
of view of the biological response of the irradiated tissue, providing at the same time 
flexibility in the use of models (Poisson Statistics for TCP and Lyman-Kutcher-Burman for 
NTCP) and parameters. The clinical analysis was based on reports from on treatment review 
and follow-up visits made by the patients periodically after the treatment. PSA was used as a 
measure of biochemical failure and correlated with calculated TCP. Also, reported 
complications were compared to NTCP values calculated by BIOPLAN. The follow-up data 
were about 2 months to 2.5 years old.  
 
Results: Complications reported after therapy were all less than grade 3 (RTOG) for the 
patients, which means only mild complications were reported. No patient reported having 
necrosis, perforation or a fistula for all the prognostic groups. The calculated average NTCP 
(mild complications) was 36.3 ± 33.3 % and it was 3.9 ± 3.6 % for severe complications. The 
calculated TCP had an average of 84.3 ± 7.4 % and no biochemical failure was detected on 
the follow-ups. As the total dose was elevated through 70-Gy, 72-Gy, 76-Gy, and 86-Gy (2 
Gy equivalent), the average TCP increased through 76.2 ± 3.8 %, 77.7 ± 2.6 %, 81.5 ± 4 % 
and 92.5 ± 2.5 %, respectively. The TCP therefore increased about 22 % by increasing 
prescribed doses from 70 Gy to 86 Gy. The relation between rectal overlap volume and the 
NTCP was not obvious (scattered). 
 
Conclusions The model predictions gave a reasonable reflection of the reported clinical 
outcome. A more comprehensive study requires derivation and use of accurate model 
parameters, and more mature follow-up data.   
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1. INTRODUCTION AND AIMS 
 
The aims of the retrospective study were: 
 To calculate biological objective functions [Tumor control probability (TCP), 
for the prostate and normal tissue complication probability (NTCP), in 
particular for the rectum] that directly determine the clinical outcome of 
patients treated at Johannesburg hospital during the years 2002 – 2003 for 
prostate cancer. These factors were calculated using radiobiological 
models.  
 To correlate the calculated TCP and NTCP with observed clinical outcome 
 To relate these biological objective functions with the volume of overlap of 
the target and the rectum. 
 To evaluate the effects of dose escalation on tumor control and rectal 
complications following radiotherapy.  
 
Presently, the evaluation of treatment plans is based on the volumetric distribution of the 
absorbed dose within the patient. However, it is seldom possible to measure dose 
distributions directly in patients treated with radiation. Data on dose distributions are 
almost entirely derived from measurements in water phantoms (which are tissue and 
muscle equivalent materials), which are usually large enough in volume to provide full 
scatter conditions for a given beam. These basic data are used in dose calculation systems 
devised to predict dose distributions in an actual patient. During the treatment planning 
process the patient is simulated by a 3-dimentional (3D) representation. The dose 
distribution within the patient is calculated using the electron density distribution 
provided by the CT slices, to correct for inhomogeneities such as bone and air cavities. 
Now that the speed of computers has increased dramatically, many treatment planning 
systems have implemented the ‘inverse planning’ approach, which uses predetermined 
criteria as an input and finds the beam configuration that satisfy them the most. 
 
However, to simulate the patient by a tissue equivalent computer program representation 
is not very accurate clinically since the response of the various organs to radiation 
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depends on many other factors that are currently not taken into account during treatment 
planning. Such factors are the volume dependence of organs to radiation, the internal 
structural organization of the functional sub-units in normal tissue, the density of the 
clonogenic cells for the targets, the hypoxic cell fraction within the tumor and the 
fractionation regime. The fractionation regime affects: 
• The repair of sublethal damage 
• The reassortment of cells within the cell cycle 
• The repopulation and  
• The reoxygenation of the cells. 
 
In order to take this information into account in the planning of the treatment one needs 
biological relevant objective functions, which describe the response of tumors and normal 
tissue to radiation according to their radiobiological characteristics. [1]
 
As a prevalent malignancy, often presenting with localized disease and therefore lending 
itself to radiation therapy (RT) during the past 40 years, prostate cancer has presented the 
opportunity to improve directed therapy by addressing the therapeutic ratio i.e. the benefit 
in disease outcome over the risk of morbidity. Because this is also a malignancy for 
which multiple effective treatment methods are available and the option of no therapy is 
still considered to be a reasonable alternative for at least some patients, it is all the more 
critical that the hazards of RT, both in terms of tumor recurrence and complications, be 
seriously considered. Recent technological improvements in treatment planning and 
delivery systems have given us the tools to improve targeting and thereby increase the 
total dose.  
 
In practice two main groups of objective functions have been used in radiation oncology, 
i.e. physical and biological objectives. The most commonly employed objective functions 
are physical and they often describe the properties of the delivered dose distribution in 
the target volume and affected normal tissue or organs at risk. Dose volume histograms 
(DVH) have been in use to quantify these physical objective functions and also to help in 
treatment optimization. The application of these latter concepts is important for accurate 
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and precise treatment. It is fundamental that the target volume and the organs at risk are 
defined with the narrowest possible safety margins in relation to anatomic reference 
points that are used for setting up the patient for external beam therapy. In principle the 
target volume should include all the volumes and margins whose dimensions cannot be 
affected by changing or developing dose planning or treatment techniques (including 
fixation of the patient).  
 
To this target volume, setup margins may later have to be added depending on the 
treatment technique and the quality of the treatment unit. It is fundamental that precisely 
this target volume should be used for dose prescription and reporting, as it is the most 
relevant one for the treatment outcome. The biological objective function aims at 
quantifying precisely this quantity, namely the probability that the patient will have the 
desirable treatment outcome. From this point of view the radiobiological objective 
function quantifies the patient’s quality of life (QOL) after therapy.  
 
To take full advantage of the available technology and to optimize and individualize 
radiation treatment, one needs tools to assess the patient’s clinical outcome of any 
radiation treatment. That is, one needs tools that quantify the probability of an end point 
of interest - say, TCP, or NTCP - as a function of the most meaningful characteristics of 
the irradiated tissue and organs (i.e. their geometry and biology). It is impossible and 
frankly unfeasible to account for all processes contributing to observed outcomes, 
however the dominant ones should be identified and modeled. [2] 
 
The main objective of this study was to predict clinical outcome. The study focused 
mainly on prostate cancer patients, treated at Johannesburg Hospital from 2002 to 2003.  
 
 The major challenge in radiation oncology is to maximise normal tissue while delivering 
sufficient dose to the target volume. The main aim of prostate treatment is to maximize 
the mean dose to the prostate and its margins and minimize the dose to the rectum and 
bladder adjacent to and often overlapping the target. This requires the use of dose-volume 
constraints to the target volume and critical structures. At Johannesburg Hospital for 
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instance, not more than 25% of the rectum is permitted to receive more than 70-Gy [3]. 
Violation of this constraint may lead to serious complications (mainly rectal 
complications).  
 
The analysis was based on the clinical patient data reported from on treatment review and 
follow-up visits made by patients periodically after the treatment. These data were of use 
in determining what complication the patients experienced after treatment. Dose volume 
histograms of the physical dose distribution (from the planning system) were used to 
calculate the treatment outcome, which was based on the calculation of radiobiological 
models used to estimate the end-point of radiotherapy treatment (TCP and NTCP).  
 
The effectiveness of dose escalation was also studied. It is a radiobiological fact that 
higher doses per fraction have a negative effect on the late reacting tissue, but may 
improve tumor control. Thus, different treatment schedules or dose prescription 
optimization will/might result in different (preferably better) treatment outcome. The 
study concentrated on how dose escalation affected the treatment outcome.  
 
Some patients might have received hormone therapy at least for 3 months before 
radiotherapy or during the course of radiotherapy. This has a direct implication on 
Prostate specific antigen (PSA) pretreatment levels before and during treatment.    
 
In prostate radiotherapy, the planning target volume (PTV) is not the gross tumor volume 
(GTV). To effectively deliver the treatment, a margin that takes care of microscopic 
disease was added to GTV, and the resulting volume is the Clinical target volume (CTV). 
To the CTV, a margin for the possible anatomical movement of the patient (bladder and 
rectum relative to prostate) and for differences in setups from different schedules was 
added, and this defined the PTV. The beams were shaped/blocked to give exact 
conformation to this PTV. This was to avoid the critical structures (rectum and bladder) 
thus, allowing the possibility of maximizing the dose to the prostate. The critical organs 
will always be exposed as there is an overlapping region, which means that part of the 
rectum and the bladder will be irradiated with high doses as well. Intuitively, the degree 
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of complications will depend on how much of the rectum is in the overlapping region. 
Hence, in order to attempt to quantify this complication, the overlap volumes were 
measured and were related to the TCPs and NTCPs calculated and observed.  
 
To calculate the TCP and the NTCP, use has be made of PC-based software. This 
software (BIOPLAN) allows the user to evaluate a treatment plan from the point of view 
of the biological response of the irradiated tissue, providing at the same time flexibility in 
the use of models and parameters. It requires information on the DVH and can accept a 
number of different formats (including DVH files from commercial treatment planning 
systems). BIOPLAN provides tools such as TCP calculations (using the Poisson model), 
NTCP calculation (using either the Lyman-Kutcher-Burman or the relative seriality 
models), the ΔTCP method, DVH subtraction, plots of NTCP/TCP as a function of 
prescription dose, tumor and organs at risk (OAR) dose statistics, Equivalent uniform 
dose (EUD), individualized dose prescription and parametric sensitivity analysis of the 
TCP/NTCP models. [1]
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2. THEORETICAL BACKGROUND 
 
2.1 Application Of Biological Models To Clinical Data 
 
A methodology for applying biological models to clinical data with the goal of being able 
to estimate the probability of control or complication in an organ or normal tissue when 
exposed to non-uniform irradiation is needed. 
 
Several normal tissue complication probability models exist, some of them 
phenomenological and others of biological nature, that try to describe the response of 
different types of normal tissue to radiation.  With the number of proposed models 
increasing in time it becomes more important to apply an appropriate methodology to 
data analysis and model validation. The methodology presented below allowed the 
retrieval of the model parameter values together with the estimates of their variances and 
the correlation between them, as well as the calculation of the uncertainty in the model 
predictions. 
 
The methodology presented here is by no means novel; it simply represents good practice 
in the analysis of data. A mistaken opinion is that sparse data do not merit so detailed an 
approach. In fact, when the data are poor, a secure analysis is all the more necessary in 
order to clarify the degree of confidence one can have in the model’s predictions. [4]
 
The methodology recommended for good practice is as follows: 
 
1. Identify the data together with estimates of confidence limits; 
2. Identify one or more models that are to be fit to the data; 
3. Perform a fit of the models to the data, for which estimates of the values of the 
model parameters and their errors (including their correlation) can be derived; 
4. Estimate the goodness of fit of the model; 
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5.  Reject models that are inconsistent with the data and either chose a model which 
best fits the data, or the model that, from a priory considerations, is preferred 
among the models providing satisfactory fits to the data; 
6. From the estimates of the model parameters and their errors, estimate the TCP 
and NTCP and the confidence limits on the NTCP for any dose distribution of 
interest. [4] 
 
It should be noted that for this study, a full analysis as presented above was not followed; 
as it was beyond the scope and aims/objectives. 
 
2.2 Radiobiological Modelling 
 
The radiation oncologist prescribes the treatment in terms of a uniform dose to the target 
volume accompanied by some sort of constraint on the dose to one or more organs at risk. 
However, the end points in radiotherapy that are truly of relevance are not dose 
distributions but the probability of local control, sometimes known as TCP and the 
NTCP. The aim of treatment is to maximize the TCP while the NTCP remains below 
some “acceptable” (usually very low) level. Figure 1 illustrates this. [2] [5]
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FIGURE 1. Schematic curves illustrating the dose-dependence of TCP (left curve) and  
NTCP (right curve); the dashed Gaussian-like curve represents the 
Probability of Complication-Free Control. [2]
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2.2.1 Tumor control probability (TCP) modelling  
 
It is well know that the dose-response curve has a sigmoid shape. Mathematical functions 
have been fitted to this curve. However, it is not easy to see how changes in basic 
parameters such as tumor cell radiosensitivity, inhomogeneities in the dose distribution, 
variation in tumor volume, in clonogenic cell density etc. can be accommodated by 
empirical curve-fitting approaches. It is however, possible to develop a TCP model 
starting from the response of cells to radiation. [2]
 
a. Basic Cell-Survival Curves  
 
The killing of cells by radiation can be described (from radiobiological experiments) by 
an expression of the form:  
 
S = exp (-αD - βD2)        (1) 
   
Where S is the surviving fraction after a (uniform) dose D of radiation to a population of 
cells. The parameters α and β characterize the initial slope and degree of curvature, 
respectively, of the survival curve. This is known as the linear-quadratic (LQ) model of 
cell killing. [2]
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FIGURE 2. Modification of the survival curve to 2 Gy fractions. [2]
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When the irradiation is fractionated as is customary in external-beam radiotherapy, for 
the almost universally adopted 2-Gy (per day) fractionation scheme, the effective slope of 
the survival curve is very nearly given by the value α alone. Figure 2 illustrates this.  
Thus one can write: 
 
Ns ≈ No exp [-αD]        (2)    
 
No is the initial number and Ns the surviving number of clonogenic cells, assumed here to 
be irradiated uniformly and to have uniform radiosensitivity α (Gy-1): the latter is 
sometimes donated by αeff . [2]
 
b. The Poisson Statistics Result 
 
The next step is to incorporate the end point i.e. the eradication of the tumor, into the 
model. There is considerable radiobiological evidence for the statement that the tumor is 
only “dead” when every single clonogenic cell (i.e. cells with the potential for 
uncontrolled division) has been eliminated. Thus the quantity of radiation required is 
limited to the probability that no single clonogenic cell survives. Equating this with TCP, 
the Poisson Statistics relation is exploited: 
 
[ sNTCP −= exp ]
)]
        (3)        
 
Substituting equation 1 into equation 3 gives 
 
([ DNTCP α−−= expexp 0       (4) 
 
Plotting this expression produces the well-known sigmoid curve. Using a realistic value 
for the number of initial clonogenic cells of the order of 109 and realistic value of α from 
a to e Gy-1 one obtains the family of curves shown in figure 3. [3] 
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Figure 3. TCP curves from equation 4 for clinically realistic values of No = 109 and 
α ranging from a to e Gy-1. Note the far from clinically realistic extremely 
steep slope that results. Note that a > b > c > d > e. [2]
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c. Consistency with clinical data 
 
Theoretical models must be compared with clinical data wherever possible. There exist, 
in the literature, a number of models predicting local control. Despite the limitations 
associated with such data i.e. uncertainties in dosimetry, inadequate patient numbers, 
imprecise clinical definition of local control, etc, there are almost no local control curves 
with slopes as steep as the ones in the figure above. This has led investigators to favor an 
empirical model to fit these clinical dose-response curves. [2]
 
Various hypotheses have been advanced over the years to explain the shallowness of the 
clinically observed local control curves. The explanation that is currently thought to be 
the most likely is inter-patient heterogeneity in the intrinsic radiosensitivity of the tumor 
cells i.e the α values. This is in contrast to the possible heterogeneity of radiosensitivity 
of the clonogenic cells within any one patient’s tumor. A very interesting analysis of the 
clinical dose response has been published by Brenner [2]. Brenner demonstrated that it 
was possible to explain the wide variations in the dose required to achieve local control 
for a number of different lesions solely in terms of variation in the number of clonogenic 
cells, assuming proportionality to the volume of the lesion. The conclusion of his study 
was that one did not need to invoke any assumptions on the variation in the hypoxic cell 
fraction with tumor size, for instance. Thus the Brenner analysis lends support to models 
for TCP based on only two parameters, intrinsic tumor cell radiosensitivity α and 
clonogenic cell density pcl, that vary with tumor type. However Brenner did not build into 
his analysis any inter-patient variation in radiosensitivity and as a consequence, the 
number of clonogenic cells No required to fit these clinical data was unrealistically small  
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The TCP model described here explicitly incorporates inter-patient variation by assuming 
that α is distributed normally amongst the patient population, with standard deviation σα . 
As one increases the value of σα the slope of the dose response curve decreases. [2]
 
Then the local control can be computed from 
  
),,()( 0∑=
l
i NDTCPgDTCP α             (5) 
              
Where TCP (α,D,No) is given by equation 4 and a fraction gi of the patients have α such 
that 
 
( )[ ]22 2/exp ασαα −−∝ iig          (6) 
 
The initial number of cells has been estimated from the product pcl x Vtgt with the 
clonogenic cell density taken to be 109. 
 
d. Inhomogeneous dose distribution 
 
The model developed thus far has assumed that all cells receive exactly the same dose. In 
radiotherapy practice this will never be the case. Thus some way is needed to incorporate 
dose distributions into the TCP model. The data that is required is the number of 
clonogenic cells No,i that receives a dose Di. This is most conveniently obtained from a 
DVH generated by a 3D treatment-planning computer. The idea of the DVH is illustrated 
in the figure below. [2]
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FIGURE 4. Schematic representation indicating how differential and cumulative 
DVHs are constructed. [2]
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Strictly what is required is the differential dose-volume distribution, dV/dD from which 
the more familiar cumulative DVH is calculated. Thus one generalizes equation 2 to be: 
 
[ ]∑
=
−=
n
i
iis DNN
1
,0 ,exp α          (7) 
 
where the summation is carried out over the n bins in the DVH. This expression should 
also be used in equation 5 in order to take the effect of both dose inhomogeneities and 
inter-patient α variability into account. A more serious limitation is probably the more 
implicit assumption that the clonogenic cell density pcl is a constant out to the edges of 
the tumor or target volume. [2]
For application into BIOPLAN, the complete model has been developed to take the form: 
 
( ) ( )ii
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Where: 
TCP (equ. 8): Corresponds to the TCP averaged over a population with variability in 
radiosensitivity (simulated as a Gaussian distribution of αi values with α mean and σα 
standard deviation) where a fraction gi of patients have αi radiosensitivity and 
 . 1=∑
i
ig
[1] 
TCP(αi, βi) (equ. 9): Represents the TCP of a patient with radiosensitivity αi and with a 
non-uniform tumour dose distribution given by {Dj,vj}. 
 
j: Refers to the jth-volume (vj) that receives a dose dj in each of the n fractions (Dj = dj x 
n). 
 
β: Parameter is allowed to vary over the population of patients such that α/β is always 
constant. 
 
γ: In order to allow cell proliferation during the course of the treatment, a final term 
working in the opposite direction to cell-killing has been added; where γ = ln2/Td.  
 
Td: The average doubling time. Defined as the time for tumor volume to double, and is 
determined by cell cycle time (Tc), the growth fraction (GF) and the rate of cell lose.[5]  
 
T:  is the overall treatment time, and 
 
Tk: the time at which proliferation begins after the start of the treatment. [1] 
 
It is possible to avoid the β-term and use instead an effective α value (αeff) 
⎟⎠
⎞⎜⎝
⎛ ⎟⎠
⎞⎜⎝
⎛+= αβαα deff 1         (11) 
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2.2.2. NTCP modeling  
 
With the introduction of 3D treatment planning systems, it has also become possible to 
calculate and evaluate the dose distribution not only in the tumor but also in the 
surrounding organs at risk. A reliable estimation of NTCP based on this 3D dose 
distribution would greatly facilitate the 3D radiation treatment planning process not only 
in deciding between rival treatment plans but also in weighing the probabilities of tumor 
control and complication. This estimation of complication probability has been the 
subject of numerous publications on various theoretical models. Unfortunately, the proper 
clinical validation of these models is still lacking for most of the normal tissues. [6]
 
As 3D conformal radiotherapy is being introduced for a number of tumor sites, 
measurable clinical complication data become available for several organs. This enables 
comparison of model predictions with the observed incidence of complication. Before 
comparing the observed incidence of complications and the model predictions with 
different parameter values, the reliability of underlying DVHs and of the scoring of 
NTCPs should be considered carefully. 
 
Several models have been developed for estimating the NTCP, based on the total 3D dose 
distribution. In the conventional phenomological models, a complex inhomogeneous 3D 
dose distribution, summarized in a DVH, is converted into a uniform dose distribution for 
the whole organ, which is estimated to yield the same complication probability as the 
original treatment plan. This reduction of a complex DVH into a single step DVH is 
based on a power relation between volume and dose with a volume exponent n. 
Subsequently, the NTCP can be estimated using a dose effect relationship for 
homogeneously irradiated whole organ volumes, which are derived from clinical data. 
The sigmoid dose-effect relation for the whole organ is described by TD50 and a 
steepness parameter, m. [6]
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Recently, models with more biological background have been developed. In these 
models, it is assumed that the normal tissue consists of functional Sub-Units (FSU) that 
are responsible for the total organ function. These functional sub-units are defined either 
structurally or functionally. A local dose effect is used to determine the probability of the 
destruction of an FSU and the NTCP is assumed to be fully determined by the number or 
fraction of surviving FSUs in the organ. For organs with serially organized FSUs (e.g. 
spinal cord and oesophagus) it is required that all FSUs survive in order to avoid 
complications. For organs with parallel-organized FSUs (e.g. Lung, liver and kidney) the 
NTCP is determined by the fraction of destroyed FSUs. To take into account inter-patient 
variability, this fraction is described by a normal distribution. [6]
 
In both models, the reduction of a multistep DVH, to a single step DVH, i.e. the effective 
dose for the whole organ, Dhom or effective uniform dose (EUD), is a crucial first step for 
NTCP calculation, since it defines the ranking of the DVHs with respect to the NTCPs. If 
this step is performed correctly, then a one-to-one relation exists between the Dhom or 
EUD and the NTCP. With respect to the DVH reduction method, the Kutcher model and 
the parallel FSU model can be classified from simple to more complicated (with more 
parameters). The relative seriality model (s model), the k-model, the critical element 
model and the critical volume model are some of the models based on cell survival 
functions.  [6]
 
Two different models have been implemented in BIOPLAN: the Lyman-Kutcker-Burman 
model (empirical) and the relative seriality model (mechanistic). 
 
a. The Lyman-Kutcher-Burman model 
 
( ) dxxNTCP ∫ ∞ −= t - 2exp21 2π     (12)  
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Where: 
 TD50(1); is the dose which uniformly delivered over the whole organ will produce a 50% 
chance of complications. 
 
v; is the fraction of the organ irradiated uniformly. 
 
m; is the steepness parameter. 
 
D; uniform dose to the tumor 
 
n; is the number of voxels 
 
TD50(1), m and n have been tabulated for different organs and specified end-points, based 
on the clinical tolerance data. [7] BIOPLAN contains a library with some of them, 
otherwise they can be entered by the user. 
 
In order to incorporate into Lyman’s model the more likely situation of a non-uniform 
irradiation of the critical organ, Kutcher and Burman gave a reduction scheme to reduce 
the DVH to an effective fractional volume uniformly irradiated to the maximum dose. 
This reduction model has also been incorporated into BIOPLAN to deal with non-uniform 
dose distributions. [6] 
 
 
 
 20
b. The relative seriality model 
 
This model to describe the probability of damage of normal tissue is based on binomial 
statistics. It accounts for serial and parallel architecture of the FSU. The expression is as 
follows: 
 
( ) svk
j
s
j
j
DNTCPNTCP
1
1
)(11 ⎥⎥⎦
⎤
⎢⎢⎣
⎡
−−= ∏
=
     (15) 
      
This describes the response of the whole organ to an arbitrary dose distribution {Dj,vj}as 
a function of the response of the whole organ to a homogeneous dose distribution. The 
number of FSU has been made to coincide with the k bins in the DVH. NTCP(Dj) can be 
expressed as 
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       (16) 
 
It is based on Poisson statistics to describe cell survival.  
Where: 
s is the relative seriality factor. 
vj defines the jth subvolume. 
γ Is the maximum relative slope of the dose-response curve and  
D50 is the whole organ uniform dose that would produce a 50% complication probability. 
 
BIOPLAN has a library of s, γ and D50 values for some critical organs and clinical end 
points but any other values can be chosen. [6] 
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c. LQ correction to the physical DVH 
 
Dose heterogeneity in an organ at risk should produce different biological effects with 
varying fraction sizes as well as total dose. None of the NTCP models given above deal 
with this fractionation-effect problem, as the parameters in them effectively correspond to 
a 2 Gy fraction. Thus, the “physical” DVH should ideally be converted to a 2Gy-
equivalent DVH before using the models. 
 
Physical doses D delivered with a dose per fraction d can be converted to the 2-Gy 
equivalent dose D2 by using the following expression: 
 
( )
( )22 +
+⋅= βα
βα dDD           (17) 
 
Equation 17 can be applied to each Dj dose-bin of a DVH. BIOPLAN has incorporated 
the option to apply the equation above to correct the physical DVH for fractionation 
effects (α/β values are freely selectable by the user). The resulting 2 Gy per fraction 
equivalent DVH is then used as the input DVH in the NTCP models described above. [6]
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2.3. Guidelines For Prostate-Specific Antigen (PSA) Following 
Radiation Therapy: Biochemical failure 
 
PSA, a serine protease normally produced in the prostate, has become a powerful tool in 
the care of men with adenocarcinoma of the prostate. Since it is usually elevated when 
the prostatic epithelium undergoes malignant transformation, it has become useful in the 
early detection of the disease and in monitoring outcome after treatment. There are many 
controversies surrounding its use in both areas. 
 
After radiation therapy, the PSA declines slowly and may never reach undetectable 
levels. Authors have reported using PSA as an end point: “Biochemical” failure has been 
used widely in the absence of clinical or histopathologic evidence of local persistence or 
recurrence or demonstrable distant metastasis. Several different definitions of 
biochemical failure have been used in the literature, which has led to difficulties in 
deciding if or when a biochemical failure has occurred in an individual patient, and has 
also made it difficult for physicians and increasingly well-informed patients to interpret 
reported experiences. [8]
 
The Board of directors of the American Society for Therapeutic Radiology Oncology 
(ASTRO) charged a committee to bring resolution to the interpretation of PSA after 
radiation therapy. A group of investigators who had contributed to the literature on 
irradiation for prostatic carcinoma met to discuss the role of PSA after irradiation.   
 
Four guidelines were established: [8] 
 
• Biochemical failure is not justification per se to initiate additional treatment. It is 
not equivalent to clinical failure. It is, however, an appropriate early end point for 
clinical trials.  
• Three consecutive increases in PSA is a reasonable definition of biochemical 
failure after radiation therapy. For clinical trials, the date of failure should be the 
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midpoint between the post irradiation nadir PSA and the first of the three 
consecutive rises (with the PSA taken in 3 or six months intervals) . 
 
• No definition of PSA failure has, as yet, been shown to be a surrogate for clinical 
progression or survival.  
• Nadir PSA is a strong prognostic factor, but no absolute level is a valid cutoff 
point for separating successful and unsuccessful treatments. Nadir PSA is similar 
in prognostic value to pretreatment prognostic variables.  
 
Despite these advantages, there are some concerns about the use of PSA testing as the 
sole determinant of treatment failure. Little is known about the natural history of the 
irradiated prostate and whether residual or reconstituted normal prostate tissue can 
manufacture PSA. If it can, then a rising post-treatment PSA may not always signal 
ongoing disease, and a growing number of men may be unnecessarily subject to 
antiandrogen therapy. Another issue is whether pretreatment factors such as prostate 
volume, pretreatment PSA, and Gleason score can influence the level at which PSA 
stabilizes after treatment. [8]
 
A clearly defined, biologically based PSA end point could solve some of these problems. 
Several different end points of PSA response are in use today:  
 
• Nadir PSA (nPSA) levels are widely used as a predictor of treatment success or 
failure. However, different investigators have chosen different nPSA values as 
significant end points, ranging from 0.5 to 4.0 ng/ml. These end points generally 
arise from statistical analyses in which either the survival or freedom from relapse 
of patients above a certain arbitrarily chosen nPSA level was compared with those 
below.  
• A variant of this was time to nPSA level. At this time however, some 
investigators suggest that a long time to nPSA level is a favorable sign, while 
others suggest that a short time to nPSA level is favorable.  
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• Rising PSA after a period of stabilization is a third marker of treatment success or 
failure. A perfectly stable   PSA after radiation therapy is widely regarded as a 
favorable sign, indicating either the complete eradication of the prostate cancer or, 
at the very least, no active tumor growth. A rising PSA is universally regarded as 
an ominous sign, indicating either local recurrence or distant disease. 
 
Finally, the treatment of prostate cancer is undergoing pronounced changes as a result of 
new data from clinical trials, correlative studies from the laboratory, and a rapidly 
evolving understanding of PSA. The consensus statement of September 1996 can only be 
considered a benchmark from which to seek greater understanding from existing data sets 
and new investigations. [8]
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2.4. Uncertainties in Biological modeling  
 
The reliability of the DVHs of normal tissues, as determined from CT-based planning, is 
dependent on a number of dose and volume effect related factors. Slice thickness and 
separation may lead to the partial volume effect and errors in size and position of normal 
structures. Physiological motion during CT scanning, inter and intra fraction, change of 
organ shape and position and patient setup deviations during a course of fractionated 
radiotherapy will have an impact on the reliability of the DVH, based on the planning 
CT. [6]
 
2.4.1 The predicted effect of dose non-uniformity 
 
TCP models, which differed only slightly from the one described here, have been applied 
to the question of the effect on TCP of both inhomogeneities in the target dose 
distribution and also uncertainities in the absolute absorbed dose determination. 
For a group of patients with tumors of exactly the same radiosensitivity i.e. σα= 0.0 even 
small inhomogeneities in dose have a disastrous effect on the TCP; which implies very 
steep dose-response curves. The message is that the appreciable inter-patient variability 
in radiosensitivity indicated clinically for many types of tumors considerably reduces the 
consequences of even moderate deviations from target dose uniformity. The corollary of 
this is the conclusion that for certain classes of tumors with steep dose-response slopes, 
notably in the larynx, only very small uncertainties in the absolute dose determination can 
be tolerated. [9]
 
2.4.2 Variation in clonogenic cell density 
 
If the model explained thus far is applied to the DVH of the target volume (the PTV in 
ICRU 50) then implicitly the assumption is made that the clonogenic cell density is 
constant over the whole of the PTV i.e. one calculates the number of clonogenic cells at 
dose Di, No,i in Equ. 7 from the product of Vo,i and pcl. However, the PTV actually 
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involves a margin for microscopic spread plus a second margin for geometrically 
inaccuracies. Thus clearly the assumption of constant pcl is quite unrealistic, the figure 5 
below illustrates this point.  
 
 
FIGURE 5. Schematic drawing illustrating the problem of the variation of the 
clonogenic cell density at the edge of the PTV. A hypothetical dose and 
cell density profile through the center of the PTV is shown. 
 
Whilst there is presently no clinical data on exactly how the cell density does vary 
throughout a radiotherapy target volume, one can use the model to assess the effect that 
such variations might have on the predicted TCP. One way of looking at this is to 
calculate the change in dose D that corresponds to a change in cell density pcl when one 
requires that the TCP remains unchanged for a given volume element of cells. Taking the 
clonogenic cell density at the tumor center say, to be ρ(0) and the corresponding quantity 
at some position r to be ρ(r), then it is straightforward to show that  the change in dose at 
r to yield the same TCP for the same size of volume element is given by 
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where the product α ΔD is proportional to the logarithm of the ratio of cell densities. 
 
Uncertainties in local radiation dose due to setup deviations and organ motion were 
studied by Kytcher and Mageras for the rectum in 3D conformal prostate treatment [9]. 
Based on the statistics of a group of 12 patients, the effect of setup deviations and organ 
motion on the DVH of the rectum for a single patient was described by confidence limit 
dose volume histograms. [9]
 
2.4.3 Uncertainties in volume and DVH of rectum and bladder during 
conformal radiotherapy of prostate cancer  
 
The effects of pattern of changes of rectum and bladder DVHs were studied by 
Warkentin B. and colleagues [10]; using Tree matched repeat CT scans. DVHs were 
calculated for all the organs using a three-field technique with an isocentric dose of 80-
Gy. To evaluate the DVHs, the high dose volumes and the NTCPs were evaluated. 
 
The variations of total rectum and bladder wall volumes during treatment were 9% and 
17% (1 standard deviation), respectively, with no time trend. The variation of total 
bladder wall was positively correlated with bladder filling variation, indicating a possible 
overestimation of bladder wall thickness, when the bladder was relatively full. The 
variation of the high dose (>80%) rectum wall volume was 14% (1 SD) and independent 
of rectum filling. As a result the variation of the NTCP during treatment was small (on 
average 3.3 %). [10] 
 
In conclusion, rectum wall DVHs can be determined reliably from CT based planning. 
However, the drawing of the inner rectum wall is labor intensive and methods need to be 
developed to generate a DVH of the rectum wall based on information of the outer 
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contour only, like the approximation of the DVH of the wall by a Dose Surface 
Histogram. The relative DVH of the bladder wall could not be determined reliably at all. 
The main reason for this failure was the inability to contour the inner bladder wall 
consistently. [6]
 
The success or failure of radiation therapy can depend upon the accuracy with which the 
dose prescription is fulfilled. For many diseases the required accuracy is not known. In 
others, the outcome of treatment depends upon tumor doses that do not vary by more than 
±5% about the optimum. The establishment of tumor-cure probabilities, optimized time-
dose schedules, and radiobiological efficiencies requires that the systematic uncertainties 
in dosimetry be made considerably smaller than the uncertainties in measuring tumor 
volume and response. This necessitates that improved accuracy be sought in the 
dosimetry of high-energy photon and electron beams. [11]  
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3. EXPERIMENTAL PROCUDURES 
 
3.1 Patient Characteristics 
 
This study was done from records of 41 patients who were treated with 3D conformal 
radiotherapy for carcinoma of the prostate at Johannesburg Hospital from 2002 to 2003, 
37 of whom had post-treatment outcome data. Data collection for these patients was 
terminated around June 2005.  
 
For patients treated in 2002, 13 were treated as intermediate risk patients with radical 
intent to 68 Gy (2 Gy per fraction) plus a boost of 8 Gy (2 Gy per fraction) and 5 were 
treated as high-risk patients to 70 Gy in 2 Gy fractions. Of the patients treated in 2003, 17 
were treated as intermediate patients with radical intent to 66 Gy in 2 Gy fractions plus a 
boost dose of 12 Gy (4 Gy per fraction), and the remaining 8 patients were treated with 
radical intent to 72 Gy in 2 Gy fractions. 
 
The age range during treatment was 54 – 79 years of age (mean age of 68.3 years) staged 
at T1 to T4, with a mean stage of II.  
 
3.2 Treatment Simulation, Planning, and Delivery 
 
The patients were treated supine in a personal polyurethane cast extending from the 
midchest to below the feet. The knees were slightly flexed to relax the lower back and 
keep the heels together when the cast was made. The patient had three tattoos made in 
midline (one for midline positioning) and one on either side for anti rotational alignment 
(one tattoo 10 cm superior and at level of the right lateral tattoo and the other tattoo 10 
cm inferior and at level of the left lateral tattoo for anterior-posterior or superior-inferior 
rotation.) [12]
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The patient was CT scanned from the lumbar spine 5 (L5) to the pelvic brim (using 1 cm 
thickness slices) and then with 0.5 cm thickness slices through the true pelvis, seminal 
vesicles and the prostate gland to below the ischial tuberosities.  
 
A six-field technique was used with the fields arranged 45 degrees apart. The gantry 
angles were 45, 90, 135, 315, 270 and 225 degrees. Using the beams eye view (BEV) and 
the margin options, the aperture blocks were drawn to coincide with the margin of 1.5 cm 
superiorly, laterally, anteriorly and inferiorly and 0.75 cm (0.8 mm) posteriorly to reduce 
the volume of the rectum in the treatment fields. Sometimes it was found necessary to use 
wedges in the lateral fields to prevent a hot spot anteriorly. Figure 6 shows a typical dose 
distribution obtained from this technique. 
 
The boost was a three-field technique with gantry 00, 900, and 2700. Figure 7 shows this 
field arrangement. This boost treatment was designed to escalate the dose to the GTV and 
spare the rectum. During the boost treatment, the treated fields were verified daily and 
positioned away from the rectum, so as to minimize its irradiation.  
 
For the main treatment course the dose prescription was to the mean (average) isodose 
level of the defined margins (Planning Treatment Volume) according to the ICRU Report 
50. For the boost, dose was prescribed to 100 % at the isocenter.  
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FIGURE 6. A CT slice, showing six conformal fields used as a standard technique in 
the treatment of radical prostate cancer in Johannesburg Hospital. 
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IGURE 7. A CT slice, showing a three-field booster. Note that the 50 % isodose 
 
F
curve is used as a guide not to overdose the rectum.  
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3.3 Follow-Up 
After treatment, the patient is expected to appear for a follow up consultation every three 
linical local control was assessed (or determined) by measuring the PSA, which was the 
 
months, which changes to six monthly after a period of one year. This is to monitor the 
patient’s progress by observing changes in the PSA after treatment and complications 
resulting from treatment.  
 
C
biochemical measure to determine local control (hence TCP). The ASTRO definition of 
biochemical failure (BF) was adopted to determine outcome for this study. According to 
this definition, biochemical failure (BF) was indicated by three consecutive rises in PSA 
after the nadir. Side effects (complications) were reported by patients on these follow up 
visits. These could be early or late complications, depending on how long after the 
treatment the patient continued to attend these follow up visits. So a retrospective review 
of these records was used to assess the (NTCP) following the treatment.  For the analysis, 
the Modified Radiotherapy and Oncology group (RTOG) system was adopted to grade 
complications. This information was correlated to the calculated Biological objective 
functions calculated by the BIOPLAN software and the overlap volume to critical 
structures. 
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3.4 Drawing Of Treatment Margins And Overlap Volume  
 
he success of treatment can be affected by any of the steps in the radiotherapy 
 the treatment planning stage defining or drawing of treatment and critical volumes is a 
 it were possible, only the diseased area would be targeted, but this is impossible, thus 
T
management of cancer including imaging, simulation, immobilization, treatment 
planning, and treatment delivery.  
 
In
challenging and important stage. This has a direct implication on the treatment outcome. 
Underestimation of the treatment volume (or the cancer) by the doctor could mean a 
number of cancer cells has might be left untreated and this could result in re-growth and 
hence treatment failure. Drawing target volumes is also limited, since interest is not only 
on visible disease (structures visible on the CT for example) but also on microscopic 
disease, movement of the structures within the patient and the day-to-day differences in-
patient set up. Hence treatment margins are defined accordingly.  
 
If
normal tissue will always be irradiated. A number of techniques are used to minimize the 
treatment of these dose-limiting organs. The task at hand is to limit the dose to these 
organs at risk to below tolerance and give as much dose to the target volume as possible. 
This is possible only if the doctor accurately defines these critical volumes (for if this is 
not done, an organ at risk might be treated to above tolerance). Volume definition is 
critical also because treatment plans are evaluated based on the DVHs calculated by the 
planning system, and these are directly influenced by volume definition and drawing. 
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3.4.1 Drawing target volume and treatment margins [13]  
 
The International Commission on Radiation Units and Measurements (ICRU) Report 50  
has given the radiation oncology community a language for the methodology used in 
image-based 3D planning for defining the known tumor, suspected microscopic spread, 
and marginal volumes necessary to account for setup variations and organ and patient 
motion. Due to limitations and practical issues when using Report 50 methodology, the 
ICRU published a supplement to Report 50 (ICRU Report 62) to formulate more 
accurately some of the definitions and to take into account the consequences of the 
advances made over time. [13]
Presented in the figure below, is the schematic diagram depicting volume definition 
according to the ICRU Report 50 
 
 
 
FIGURE 8. Schematic illustration of the boundaries of the volumes defined by ICRU   
   50. 
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3.4.2 Clinical target volume (CTV), and planning target volume (PTV)  
  
The ICRU Report 50 definition of target volume is separated into three distinct 
boundaries:  
1. Visible tumor- Gross Tumor Volume  
2. Region to account for uncertainties in microscopic tumor spread- Clinical Target 
Volume , and 
3. A region to account for positional uncertainties - Planning Target Volume  
 
The GTV; The GTV is the gross demonstrable extent and location of the malignant 
growth. It consists of the primary tumor and possibly metastatic lymphadenopathy or 
other metastases. The GTV almost always corresponds to those parts of the malignant 
growth where the tumor cell density is the highest. 
 
The CTV; the CTV is the tissue volume that contains a GTV and/or subclinical 
microscopic malignant disease. In specifying the CTV, the physician must consider 
microextensions of the disease near the GTV, and the natural avenues of spread for that 
particular disease and site including lymph node, perivascular, and perineural extensions. 
 
The PTV; The PTV is the geometrical concept used for treatment planning, and is 
defined to select appropriate beam sizes and beam arrangements, to ensure that the 
prescribed dose is delivered to the CTV. To avoid significant deviation from the 
prescribed dose in any part of the CTV, one must add margins to the CTV for variation in 
tissue position, size, and shape, as well as for variations in patient position and beam 
position, both intrafractionally and interfractionally. This leads to the concept of PTV. 
 
For planning in Johannesburg hospital the PTV was defined by the internal margin and 
was used to define the personalized conformal prostate shielding blocks. Beam shaping 
blocks were drawn using the beams-eye-view option for all the six fields. A schematic 
diagram to illustrate this is shown in figure 9.  
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FIGURE 9. Diagram showing a typical conformal block defining the treatment field 
and indicating the size of the margins allowed on all sides of the GTV. 
The margin is 1.5 cm all around the GTV but only 0.8 cm over the rectum 
side. 
 
The distances indicated the PTV’s outer boundary. The PTV or block boundary is drawn 
at 1.5 cm from the GTV boundary all around the prostate itself except posterior, were the 
margin is at 0.8 cm from the GTV. This is thought to minimize the dose to the rectum 
when using this technique. [13]
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3.4.3 Drawing the overlap volume 
 
The overlap volume in this study was the volume of the rectum that coincided with the 
planning target volume. This was defined on the Helax TMS for the purpose of a DVH 
estimation by demarcating it on every CT slice where the volumes intercepted each other, 
as illustrated in figure 10 below.   
 
 
FIGURE 10.   This diagram depicts the overlap volume defined by the intersection of 
   the rectum and the PTV. 
 
After all the volumes had been drawn, the plan was sent for recalculation. Dose Volume 
Histograms for the GTV, Margins (PTV), Rectum, Bladder, and Overlap Volume were 
calculated. 
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3.5 DVH Data Transporting And Calculation Of Biological 
Objective Functions Using BIOPLAN 
 
 
Use BIOPLAN to convert 
the files to BIOPLAN 
format automatically 
Transfer files to 
BIOPLAN format 
Using manual 
manipulation 
Choosing Parameters
DVH file  
Helax format 
To a Windows file
Dose volume Histogram
(DVH) 
Helax TMS 
 
 
 
 
 
 
 
 
 
 
 
 
BIOPLAN OUTPUT     
 • TCP, NTCP, UTP vs. dose 
• TCP vs. α 
• TCP distribution 
• Customized dose etc. 
• A plot of DVH (in percent or absolute) 
 
 
 
 
 
 
FIGURE 11. Flow chart indicating the flow of data execution in BIOPLAN 
calculations. 
 
BIOPLAN is computer software for the biological evaluation of treatment plans, and has 
been developed using Visual Basic version 3.0. BIOPLAN requires DVHs in ASCII 
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format, a file for each volume or structure. The files from Helax were converted into 
BIOPLAN format either manually or using tools provided by BIOPLAN to do this 
automatically. Figure 11 indicates the flowchart to process or calculate biological 
objective functions from Helax TMS input files.  
 
3.5.1 DVH data transporting and file preparation 
 
DVH data for the GTV, PTV, Rectum, Bladder, and overlap volumes were transported 
for each patient via ftp to a networked LANTISTM (Local area network therapy 
information system) computer. In the process, each DVH was given a file name and the 
data points were converted into absolute values of dose and volume. To serve as 
meaningful input to BIOPLAN, these files were converted to BIOPLAN format either by 
manual manipulation or automatically, by BIOPLAN itself.  
 
3.5.2 Calculating biological objective functions 
 
DVH files give only physical data about a treatment plan. To initiate biological 
calculations, model parameters were chosen. BIOPLAN has default parameter values for 
most critical structures and for the prostate. In particular, the default α/β ratio for the 
prostate is 10 Gy-1 although it is known to be much smaller than this (= 1.5 Gy-1). For this 
study and for consistency, all default values from BIOPLAN were used for the 
calculations. The default parameters used are given in table 1 below.  The α/β ratio of 1.5 
Gy-1 was also used in the calculation to compare with TCP and NTCP resulting from the 
default α/β value. 
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Tissue Parameter Type of complication Value 
α/β - 10-Gy  
α - 0.292-Gy-1
SD of α - 0.07 
Cell density - 1.1 X 10 7 cm3
Tumor 
(Prostate) 
 -  
Mild (as defined by RTGO) 0.064 m 
Perforation, necrosis, fistula 0.15 
Mild (as defined by RTGO) 0.203 n 
Perforation, necrosis, fistula 0.12 
Mild (as defined by RTGO) 56 
Organ at risk 
(Rectum) 
TD50 
Perforation, necrosis, fistula 80 
 
TABLE 1. This table gives default values of the parameters used in BIOPLAN 
calculations. 
 
Calculations for prostate tumours were done ignoring effects of proliferation, as it is a 
very slow (approximately has Td = 40 days) growing tumor. Thus for all the calculations, 
proliferation is not taken into account. [1] After the selection of the appropriate parameters 
for the prostate and the rectum, the software was commanded to do all the calculations. 
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4. RESULTS  
4.1 Follow-Up Results 
 
As mentioned previously, follow-up review of the patient after treatment is part of the 
holistic cancer management program. After treatment review is of paramount importance 
since it serves as a feedback or report on the response of the treated area or quality of life 
of the patient after treatment. The quality of life of the patient is measured against 
optimum tumor control with complications (morbidity) kept as low as possible. Thus, 
follow-up reviews should quantify tumor management based on tests done on the patient 
and reports by the patient of any problems encountered after irradiation. 
 
For this study special attention was given the measure of tumor control (PSA levels, 
indicating biochemical control for the prostate) and rectal complications reported by the 
patient after treatment noting that the reviews were at least 2 months to about 2.5 years 
after treatment. 
 
The ASTRO guidelines for biochemical failure (Three consecutive rises in PSA after 
radiotherapy) were adopted for this study. 100 % biochemical control was obtained in 
this sample.   
 
Reported complication probabilities are graded according to the modified RTOG 
morbidity scale. Table 2 gives an indication of complications for each grade. [13]
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Grade Description 
1 Mild diarrhea, mild cramping, bowel movement 5/day, slight rectal 
discharge or bleeding 
 
2 Moderate diarrhea and colic, bowel movement 5/day, excessive rectal 
mucus or intermittent bleeding 
 
3 Obstruction or bleeding requiring surgery, coagulation procedure, or 
transfusion 
 
4 Necrosis, perforation, fistula 
 
 
TABLE 2. Modified RTOG morbidity scale for late rectal toxicity. [13]
 
 
Complications reported after therapy were all less than grade 3 (RTOG) for the patients, 
which means only mild complications were reported. No patient reported having 
necrosis, perforation or fistulae for all prognostic groups.  
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4.2. Tumor Control Probability 
 
4.2.1 Tabulated results 
 
Table 4 below shows all the BIOPLAN calculated biological objective functions for the 
patients included in the study. Some of the patients had no follow-up. A column of the 
absolute GTV volumes and Overlap volumes per patient is included   
 
As mentioned in the methods, default parameters were used in the calculations of these 
biological functions unless otherwise stated. 
 
Two columns are shown for the NTCP results, one predicts severe complications 
(perforation, necrosis, fistula) to the rectum while the second shows the probability of 
mild complications.  
 
All the doses used in these results were converted to 2Gy (ID2) equivalent dose.  
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Patient  GTV  Overlap  TCP (%) TCP (%) NTCP  NTCP 
No. Volume (ccm) Volume (ccm) α/β = 10 α/β = 1.5  (Proc/nect) (%)  (mild) (%)
1 64.37 2.40 90 99.7 4.20 69.30 
2 102.72 68.50 92.4 99.7 1.70 7.50 
3 78.94 8.03 90.8 99.2 3.30 49.90 
4 114.41 0.79 90.5 99.3 0.50 0.10 
5 76.03 3.06 89.7 99.2 1.50 7.50 
6 100.21 11.95 89.4 99.0 5.10 78.60 
7 121.50 15.06 90.6 99.7 4.60 61.90 
8 83.41 3.48 91.9 99.2 1.90 18.20 
9 75.52 19.37 92.8 99.4 3.90 47.90 
10 84.14 6.09 90.7 99.1 2.40 21.30 
11 78.50 1.22 93.5 99.2 4.30 77.10 
12 84.36 12.30 93.4 99.1 0.90 0.90 
13 111.05 5.95 95.9 99.0 1.80 10.30 
14 142.85 18.78 97.1 99.4 4.10 55.30 
15 47.08 12.79 97.1 99.4 0.40 0.00 
16 124.43 17.86 86.1 99.9 7.70 89.80 
17 54.06 10.15 80.7 100.0 3.90 27.40 
18 75.68 5.76 86.2 99.9 4.20 50.60 
19 101.26 4.50 80 99.9 0.50 0.00 
20 110.67 19.44 71.1 99.9 4.70 43.60 
21 99.01 11.47 85.5 99.9 2.90 18.60 
22 70.82 11.20 81.9 99.9 5.00 48.40 
23 85.19 2.65 80.7 100.0 6.80 83.20 
24 88.46 16.88 80 99.9 6.80 80.60 
25 98.65 18.11 80.6 100.0 16.90 99.30 
26 92.51 4.23 82.1 100.0 8.10 86.70 
27 110.94 14.94 84.8 99.9 2.70 19.30 
28 108.03 23.30 80.1 99.0 1.30 3.50 
29 58.87 15.62 74.4 100.0 3.40 21.50 
30 102.93 0.40 71.2 100.0 0.80 0.10 
31 79.40 6.62 81.2 100.0 16.70 99.10 
32 57.74 2.00 78.1 100.0 0.20 0.00 
33 45.67 5.24 75.9 100.0 3.60 18.60 
34 113.62 4.96 74.2 100.0 4.80 41.20 
35 46.22 9.65 78.9 100.0 1.90 1.00 
36 94.53 2.72 75.2 100.0 5.50 64.80 
37 90.64 4.95 75.4 100.0 7.20 79.80 
38 55.05 8.94 77.9 100.0 1.80 0.80 
39 53.8 4.92 78.2 100.0 2.40 5.30 
40 23.29 3.52 82.2 100.0 1.60 0.90 
41 43.68 2.04 79.3 100.0 1.30 0.70 
 
TABLE 3. Table of results calculated by BIOPLAN.  
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4.2.2 TCP vs dose (dose escalation) 
 
Figure 12 shows a graphs of the calculated TCP as a function of the prescribed dose for a 
α/β=10. This effectively summarizes the dose escalation results calculated from 
BIOPLAN.  
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FIGURE 12. Graph showing how the calculated TCP varied with prescribed dose. 
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4.2.3 TCP vs mean dose to tumor 
 
The schematic diagram below shows how the TCP varied with the mean dose to the 
target volume or GTV.  
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FIGURE 13. Tumor control probability plotted against mean dose to the GTV.  
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4.2.4 TCP vs GTV 
 
Figures 14 show how the calculated TCP varied with GTV volume.  
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FIGURE 14. TCP vs PTV volume for all dose prescriptions.  
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4.3 Normal Tissue Complication Probability 
 
TCP depends on a number of factors, but in this case only the dependence of rectal 
.3.1 Effects of dose escalation on rectum complications
N
NTCP on dose and overlap volume was studied.  
 
4  
he effect of dose escalation on predicting rectal complications (NTCP) is shown in the 
 
T
figures below. The first graph depicts the change in NTCP with dose for severe rectal 
complications and the second graph show it for mild conditions.  
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IGURE 15.  NTCP plotted against prescribed dose for severe conditions. 
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FIGURE 16. NTCP vs dose for mild complications 
on rectum complications
 
4.3.2 Effects of increased volume of overlap  
our 
ries, which represent dose prescription regimes. The diagram shows how NTCP for 
 
A graph of calculated NTCP against volume of overlap is shown. This graph shows f
se
equal overlap volumes changes with dose as well as how overlap volume changes affect 
the NTCP at a certain dose level. 
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FIGURE 17. The change in NTCP (%) with changing overlap volume. 
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5. DISCUSSION 
5.1 Follow-Up Data 
 
 
Patients were stratified into t  of pretreatment PSA level, 
Gleason score, and American Joint Comm sion on Cancer (AJCC) T stage; low risk 
fered from 
ethodologic problems, including small sample sizes, use of different definitions of 
is study, the small sample size of 37 patients was the major limiting factor. This 
as compounded by short-term follow-up, which introduced big statistical uncertainties 
d above, short follow-up times are a major problem in such studies. 
eriodical follow-ups after treatment for this study are from a few months to about 2 
 
hree risk groups on the basis
is
(stage T1-T2 and Gleason score =6 and PSA =10 ng/mL); intermediate risk, stage T1-T2 
and Gleason score 7 or PSA 10.1–20 ng/mL; and high risk, PSA =20 ng/mL or Gleason 
score =8. Patients with T3/T4 disease are classified as high-risk patients. [14]  
 
Nonrandomized clinical trials of 3D-CRT for prostate cancer have suf
m
biochemical failure, selection bias, a mixed range of treatment doses, and short follow-up 
time. 
 
For th
w
in the study. 
 
As mentione
P
years. This is problematic in this particular analysis because the accuracy of determining 
TCP and biochemical failure is very dependent on the maturity of the data. Biochemical 
failure as defined in section 2.3, is time dependent. So the study is limited by this 
immaturity of the clinical data. Most rectal complications develop at least 3 years after 
treatment. For a complete and accurate analysis, at least 5 years is the time frame 
recommended [15]. Thus the follow up results of this study were analyzed with this 
limitation in mind.  
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The benefit of dose escalation is known to be most apparent in patients with intermediate-
rom our follow up data, the results suggest that for all our 37 patients, the aim of 
ectal complications reported on the last day of follow-up for all patients suggested only 
5.2 Tumor Control Probability
risk features.[14]
 
F
treatment – Biochemical control – was achieved. For all patients, no 3 consecutive rises 
in PSA were found, which suggests local control. But this high success in local control 
may be attributed to small sample size and the short time of follow up data. 
 
R
mild or minor complications. According to the RTOG grading system, the reported 
complications are of grade 3 or less.  
 
 
 
.2.1 TCP vs dose (dose escalation)5  
ecause radiotherapy is a local therapeutic modality, the emphasis has long been on 
 is very important to note that the calculations with these models do not take care of all 
CP vs prescribed dose normalized to 2-Gy per fraction equivalent was calculated for 
four different dose prescriptions. The calculated TCP were arrived at after making a 
 
B
developing methods to affect better local control. In the case of prostate cancer, the 
current prevailing hypothesis centers on delivering higher doses to the gland. The 
necessary technology for treatment planning, delivery, and target localization to support 
this has recently become available.  
 
It
clinical characteristics of the tumor. For instance, the model does not give provision for 
the fact that patients can be classified in different prognostic groups. As a result, the 
models give results representative of grouping only and will not show the dependence of 
dose escalation on any prognostic grouping of patients.  
 
T
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number of assumptions in the calculation chain, which determine the level of accuracy 
for the results. The effects of tumor proliferation are not taken into account in the 
calculation, which underestimates the fact that the tumor is growing as it is treated. This 
is because the prostate tumor is very slow growing, and its growth was considered 
negligible.  
The model also ignored any oxygenation effects. Changes in tumor local control 
probability (TLCP) vs. total dose curves have been shown to deviate from sigmoidal 
lculation as this 
hoice was made because BIOPLAN suggested this value for the prostate and that the 
d the general trend that the TCP increased with increasing the total dose 
 the gland. The calculated TCP had an average of 84.3 ± 7.4 %. As the total dose was 
curves when hypoxic fractions are not included in the model for TCP. [16] 
 
It is also important to note that, the α/β ratio of 10-Gy was used for the ca
c
results obtained with this value were comparable to clinical outcomes. This value is in 
marked contrast to α/β of less than 3-Gy, suggested in the recent analyses [17] [18]. For 
comparison, an α/β of 1.5-Gy was also used. All other parameters were taken as given in 
BIOPLAN, thus these might have a significant contribution in the uncertainty associated 
with such results 
 
The results showe
to
elevated through 70-Gy, 72-Gy, 76-Gy, and 86-Gy, the average TCP increased through 
76.2 ± 3.8 %, 77.7 ± 2.6 %, 81.5 ± 4 % and 92.5 ± 2.5 %, respectively. The TCP 
increased about 22 % by increasing prescribed doses from 70 Gy to 86 Gy.  
 
5.2.2 TCP vs GTV 
 
It is important to note that in this analysis, the CT volume was probably an over 
stimation of true volume. In Johannesburg, the whole organ (prostate) is targeted and e
not just the tumor, so the planned volume (GTV) does not strictly conform to the actual 
tumor. This would require magnetic resonance spectroscopy (MRS) imaging, which 
would make visible the tumor within the prostate gland. The initial PSA gives a more 
accurate indication of tumor volume, which is why it is such an important prognostic 
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factor. Another prognostic factor that may be interesting to compute is the PSA density 
i.e. PSA/Volume. It may be of interest to try to incorporate these parameters into the 
models. 
   
The present model predicted a decreasing probability of achieving complication free 
or control with increasing tumor size and increasing volume of normal tissue 
r to maintain the same level of local control.  
tum
irradiated. As mentioned above the TCP is expected to vary with the target volume. In 
general, the TCP should decrease as the tumor volume increases, as long as the tumor 
dose remains unchanged. This is because more cells have to be destroyed with the same 
tumor dose. The results shown in figure 14 show no apparent variation of TCP with GTV 
for the 86 Gy, 76 Gy and 70 Gy dose prescriptions. Even when the GTV increased three 
fold, the TCP showed no major change. It has been shown from other studies that the 
TCP at constant doses does not always decrease with increasing volume [19].  But, for the 
72 Gy prescription, it showed that the TCP decreases when the GTV increases. The 
decrease is from around 82 % to about 74 % when the volume increases about 5 times its 
initial value.  
This last result suggests that as the tumor volume increases, high doses are to be 
delivered orde
 
5.2.3 TCP vs mean dose 
 
Dose escalation translates to increasing the mean dose delivered to the GTV. Increases in 
e mean dose to the tumor predicted better control of the tumor. The TCP changes faster th
for lower doses but as the mean dose increased the TCP increased further, but the rate at 
which TCP increased, decreased. This trend continued until a threshold was reached 
where the TCP remaind more or less the same even if the mean dose increased. This 
threshold indicated that dose escalation increased TCP only up to a point above which 
there would be no more theoretical gain from increasing the dose. 
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5.3 NTCP 
ortant to note that for a number of normal tissues, the incidence and severity 
f late complications are not only dependent on radiation dose and irradiated volume, but 
 
It is very imp
o
on a number of other factors as well. For example, for late rectum complications, patient-
related factors such as hypertension, diabetes, previous surgery, vascular disease, 
adjuvant chemotherapy, homone manipulation prior to radiotherapy and previous bowel 
disease may predispose the rectum to radiation injury. Furthermore, late side effects seem 
to be correlated to acute side effects as well.  
 
5.3.1 NTCP vs dose 
 
Dosimetric, anatomic, and clinical factors correlate with late rectal toxicity after three-
imensional conformal radiotherapy for prostate cancer. (The models used for the study 
eant to give the 
est result to the patient. A dose volume constraint is used to ensure that treatment 
s. There 
re three dose regimes of 70 Gy, 72 Gy and 85 Gy. The results showed that the average 
raph. The graph predicts that 
creasing the prescribed dose did not alter the NTCP significantly. The reason might be 
that for all plans, if a volume more than 25 % of the PTV received doses more than 70 Gy 
d
do consider these factors in the calculation but not all e.g. the effects of hypoxia and 
chemotherapy to treatment outcome are not included in the calculation.) 
 
Dose-volume constraints used in evaluating and accepting plans are m
b
objectives are met, achieving optimum control and keeping complications low. For this 
study, mild conditions are expected with high probability. But serious complications are 
expected to be less than 5 %, because of the initial dose volume constraint used.  
 
Figure 15 shows NTCP vs delivered dose was calculated for severe complication
a
NTCP was 3.9 ± 3.6 %, which is within the accepted 5 %.  
 
The effects of dose escalation were not apparent in this g
in
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then that plan would be rejected. Thus this dose-volume constraint controls the level of 
morbidity and control after RT not the prescribed dose.  
 
The calculated average NTCP (for mild complications) was 36.3 ± 33.3 %. There was no 
trend showing of increasing NTCP as the dose increases.  
 
5.3.2 NTCP vs overlap volume  
 
The rationale for 3-dimensional conformal radiotherapy (3D-CRT) and intensity-
safe dose escalation to tumors may be achievable 
 the volume of adjacent normal tissue exposed to high radiation doses can be kept 
behave as continuous 
terrelated variables, because both the absolute and the percentage of rectal volume 
rgan makes sense as a way of 
mmarizing the dose–volume distribution. However, for “hollow” organs, such as 
modulated radiotherapy (IMRT) is that 
if
within acceptable limits. To understand these limits in terms of dose and volume, many 
studies have been performed to estimate the risk of normal-tissue complications as a 
function of the dose distribution to tissue summarized in the form of a dose–volume 
histogram (DVH). Although the DVH does not retain spatial information (i.e., which part 
of the organ is exposed to which dose), it nonetheless provides considerable information 
regarding the dose–volume characteristics of the treatment plan. [7] 
 
Dose volume histogram analysis clearly indicates a volume effect on the probability of 
developing late rectal complications. The dose and the volume 
in
correlate significantly with late toxicity across a range of doses. Studies show that the 
risk of developing late rectal complications grows exponentially as a more absolute 
volume of the rectum is irradiated to a defined dose. [7] 
 
For “solid” organs, such as liver, lung, and parotids, use of a DVH based on the entire 
volume encompassed by the outer contour of the o
su
rectum and bladder, the contents of the organ are irrelevant to the risk of complications 
that may occur as a result of radiotherapy (RT). For this reason, the dose–wall histogram 
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and dose–surface histogram (DSH) have been proposed as alternatives to the DVH for 
such organs. [7] 
 
These results showed scattered data for all dose regimes. This suggested that the 
irradiation of a bigger rectum volume does not increase the chances of rectum 
omplications.  
l toxicity than do models based on the DVH seems intuitively clear 
ecause of the irrelevance of the dose received by the rectal contents. However, the DWH 
ghtly improved when the analysis was based on the rectal DWH instead of on 
e DVH. Thus, the use of DVH instead of DWH might have an influence on the results 
c
 
At first glance, the notion that NTCP models based on the DWH would better describe 
the risk of recta
b
assessed from the planning CT is not necessarily an accurate representation of the true 
dose distribution to rectal wall during treatment. Numerous studies have demonstrated 
that considerable variation may occur in the shape and position of internal organs, 
including rectum, during the course of RT for prostate cancer. This variation is largely 
caused by interfractional differences in rectal and bladder filling over the course of 
treatment. In addition, the DVH and DWH have fairly similar shapes. Therefore, whether 
NTCP modeling based on the DWH (especially a semiauto-contoured DWH) would in 
fact be more accurate than NTCP modeling based on the DVH is not immediately 
obvious. [7]
 
Some studies have shown that for each of the models, the fit to the late rectal bleeding 
data was sli
th
and relationships between dose and volume.  
 
5.4 A Comparison Of Calculated To Clinical Follow-Up Results 
 
Dose-volume constraints used to keep the incidents of complications within specified 
l  
eatment plan.  
evels, at least for a given period of time, are a useful tool in radiotherapy to co-evaluate a
tr
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 The constraint used in this study to keep severe rectal complications to 5 % within a 5-
year period to maintain local control within acceptable levels was used. In order to 
chieve such results, the plans were passed on the condition that at least not more that 25 
 level (section 4.3.1). This showed 
at our calculations were within clinical acceptable results. This gives strong support to 
data 
ported in this study, an agreement to calculated results was found (section 4.3.1). An 
a
% of the rectal volume would recieve 70 Gy or more.  
 
Our calculated results (from BIOPLAN) showed a high percentage of severe rectal 
complications being maintained within the 5 % NTCP
th
the success of the treatment regimes used. Such agreement between modeled and 
expected results validated the models and to a certain accuracy, the parameters used. 
 
Mild rectal complications were also calculated. These were found to be highly probable 
and were expected to increase with increasing prescribed dose. With the follow-up 
re
analysis done on patient files revealed that a high percentage of mild (not serious) 
complications were reported from follow-ups as per the calculated NTCPs. This in 
general, shows that the models gave results related and close to the clinical ones. The 
modeled results on dose escalation showed the increase in TCP with dose (section 4.2.2). 
This was the case for all the patients in this study. But clinically, the significance of dose 
escalation on Low and high-risk patients is not expected. Gains in TCP are expected only 
for intermediate patients as the dose is increased. This is because the models used in this 
study did not take care of differences in prognostic grouping in its calculation.   
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6. CONCLUSIONS 
 
 The use of BIOPLAN e from DVH data exported 
from the Helax TMS at Johannesburg was successful. 
 
ical prognostic. It has been 
found that dose escalation is not beneficial for all prognostic groups. Some studies 
  
egimes, which was not expected. A clear decrease in TCP 
ith increased target volume was observed for only one dose regime. Use of GTV 
 
 
complications will be 
within 5 % But mild conditions (less than or equal to grade 3) can go up to a 
 
 
 increased. This was unexpected since an increase in rectal 
irradiation should translate to an increase in complications.     
 
 
tions with current 
technology, is encouraging.  
 to predict biological outcom
 Dose escalation has been found to improve local control. The calculation does not 
classify different patients according to their factors clin
have shown that dose elevations improve local control (Biochemical control) for 
intermediate risk groups only; no improvements are reported for low and high risk 
groups. The model therefore predicted an increased TCP with dose escalation for 
all patients groups.   
 
The TCP vs tumor dose study showed no variation in TCP with GTV size (tumor
size) for three dose r
w
alone therefore was inadequate to accurately predict TCP. 
The NTCP vs dose results confirmed that if not more than 25 % of the rectal 
volume receive more than 70-Gy then grade 3 or more 
NTCP of 100 %. 
This study did not show any increase in rectal complication as the overlap volume 
(rectal wall) was
Mature follow-up data is a requirement for studies of prostate cancer, however the 
ability to correlate physical and biological objective func
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 With the improvement/maturity of our clinical data and the increased number of 
prostate cases, a proper study can be done. This includes the derivation of model 
parameters fitted from our clinical data. This would improve the predictive value 
 
 
f the dose volume histograms (DVH).   
tumor eradication by 
irradiation, excluding proliferation and re-oxygenation effects. The main 
 
 
 
 
of these models. 
Perhaps a more realistic dose wall histogram (DWH) tool might be used for future 
analysis, instead o
 
 The TCP model described here is mathematically very simple and yet it is a 
reasonably complete description of the process of 
limitations in its use are lack of clinical data on radiosensitivity and clonogenic 
cell density. Thus the absolute values of TCP (and for NCTP) predicted must be 
treated with caution. 
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